nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR1D—meninx—peripheral nervous system neoplasm	0.0262	0.0867	CbGeAlD
Loxapine—HTR1B—dura mater—peripheral nervous system neoplasm	0.0249	0.0825	CbGeAlD
Loxapine—HTR1D—dura mater—peripheral nervous system neoplasm	0.0241	0.0798	CbGeAlD
Loxapine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0141	0.0466	CbGeAlD
Loxapine—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.0119	0.0395	CbGeAlD
Loxapine—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.0107	0.0355	CbGeAlD
Loxapine—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0104	0.0343	CbGeAlD
Loxapine—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.00909	0.0301	CbGeAlD
Loxapine—HTR7—vagus nerve—peripheral nervous system neoplasm	0.00772	0.0256	CbGeAlD
Loxapine—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.00762	0.0253	CbGeAlD
Loxapine—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.00738	0.0245	CbGeAlD
Loxapine—HTR6—ganglion—peripheral nervous system neoplasm	0.0064	0.0212	CbGeAlD
Loxapine—DRD5—ganglion—peripheral nervous system neoplasm	0.00623	0.0207	CbGeAlD
Loxapine—HTR7—cranial nerve—peripheral nervous system neoplasm	0.00588	0.0195	CbGeAlD
Loxapine—HTR7—pons—peripheral nervous system neoplasm	0.00581	0.0192	CbGeAlD
Loxapine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00515	0.017	CbGeAlD
Loxapine—DRD1—nerve—peripheral nervous system neoplasm	0.00482	0.016	CbGeAlD
Loxapine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.00481	0.0159	CbGeAlD
Loxapine—DRD1—ganglion—peripheral nervous system neoplasm	0.00476	0.0158	CbGeAlD
Loxapine—HTR3A—nerve—peripheral nervous system neoplasm	0.00466	0.0154	CbGeAlD
Loxapine—HTR3A—ganglion—peripheral nervous system neoplasm	0.0046	0.0152	CbGeAlD
Loxapine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00388	0.0128	CbGeAlD
Loxapine—HTR1B—ganglion—peripheral nervous system neoplasm	0.00386	0.0128	CbGeAlD
Loxapine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.00383	0.0127	CbGeAlD
Loxapine—HTR1D—ganglion—peripheral nervous system neoplasm	0.00374	0.0124	CbGeAlD
Loxapine—HTR2C—ganglion—peripheral nervous system neoplasm	0.0037	0.0123	CbGeAlD
Loxapine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00367	0.0121	CbGeAlD
Loxapine—HTR2A—pons—peripheral nervous system neoplasm	0.00362	0.012	CbGeAlD
Loxapine—HTR1E—brainstem—peripheral nervous system neoplasm	0.00355	0.0117	CbGeAlD
Loxapine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00351	0.0116	CbGeAlD
Loxapine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00313	0.0104	CbGeAlD
Loxapine—HTR1A—ganglion—peripheral nervous system neoplasm	0.00311	0.0103	CbGeAlD
Loxapine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00309	0.0102	CbGeAlD
Loxapine—HTR7—nerve—peripheral nervous system neoplasm	0.00301	0.00998	CbGeAlD
Loxapine—HTR7—ganglion—peripheral nervous system neoplasm	0.00298	0.00986	CbGeAlD
Loxapine—DRD2—nerve—peripheral nervous system neoplasm	0.00285	0.00944	CbGeAlD
Loxapine—DRD2—ganglion—peripheral nervous system neoplasm	0.00281	0.00932	CbGeAlD
Loxapine—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.00226	0.00749	CbGeAlD
Loxapine—DRD1—brainstem—peripheral nervous system neoplasm	0.00207	0.00686	CbGeAlD
Loxapine—HTR3A—brainstem—peripheral nervous system neoplasm	0.002	0.00662	CbGeAlD
Loxapine—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.0019	0.00628	CbGeAlD
Loxapine—HTR2A—nerve—peripheral nervous system neoplasm	0.00188	0.00623	CbGeAlD
Loxapine—HTR2A—ganglion—peripheral nervous system neoplasm	0.00186	0.00615	CbGeAlD
Loxapine—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00183	0.00608	CbGeAlD
Loxapine—HTR1B—brainstem—peripheral nervous system neoplasm	0.00168	0.00556	CbGeAlD
Loxapine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.00166	0.00551	CbGeAlD
Loxapine—HTR1D—brainstem—peripheral nervous system neoplasm	0.00162	0.00538	CbGeAlD
Loxapine—CHRM1—parotid gland—peripheral nervous system neoplasm	0.00162	0.00536	CbGeAlD
Loxapine—HTR2C—brainstem—peripheral nervous system neoplasm	0.00161	0.00533	CbGeAlD
Loxapine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.00152	0.00505	CbGeAlD
Loxapine—HTR1A—brainstem—peripheral nervous system neoplasm	0.00135	0.00448	CbGeAlD
Loxapine—ADRA2C—trigeminal ganglion—peripheral nervous system neoplasm	0.00134	0.00445	CbGeAlD
Loxapine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.00134	0.00445	CbGeAlD
Loxapine—HTR7—brainstem—peripheral nervous system neoplasm	0.00129	0.00429	CbGeAlD
Loxapine—ADRA2C—parotid gland—peripheral nervous system neoplasm	0.00127	0.0042	CbGeAlD
Loxapine—ADRA1A—brainstem—peripheral nervous system neoplasm	0.00125	0.00413	CbGeAlD
Loxapine—DRD2—brainstem—peripheral nervous system neoplasm	0.00122	0.00405	CbGeAlD
Loxapine—HRH1—trigeminal ganglion—peripheral nervous system neoplasm	0.00109	0.00362	CbGeAlD
Loxapine—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.00107	0.00355	CbGeAlD
Loxapine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.00082	0.00272	CbGeAlD
Loxapine—HTR2A—brainstem—peripheral nervous system neoplasm	0.000807	0.00267	CbGeAlD
Loxapine—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000804	0.00176	CcSEcCtD
Loxapine—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.000798	0.00175	CcSEcCtD
Loxapine—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.000797	0.00175	CcSEcCtD
Loxapine—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000795	0.00174	CcSEcCtD
Loxapine—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.000795	0.00174	CcSEcCtD
Loxapine—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000794	0.00174	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—peripheral nervous system neoplasm	0.000788	0.00173	CcSEcCtD
Loxapine—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.000784	0.00172	CcSEcCtD
Loxapine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000769	0.00169	CcSEcCtD
Loxapine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000767	0.00168	CcSEcCtD
Loxapine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000767	0.00168	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—peripheral nervous system neoplasm	0.000762	0.00167	CcSEcCtD
Loxapine—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.000758	0.00166	CcSEcCtD
Loxapine—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.000755	0.00165	CcSEcCtD
Loxapine—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000752	0.00165	CcSEcCtD
Loxapine—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.00075	0.00164	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000745	0.00163	CcSEcCtD
Loxapine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.00074	0.00162	CcSEcCtD
Loxapine—Shock—Alitretinoin—peripheral nervous system neoplasm	0.00074	0.00162	CcSEcCtD
Loxapine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000737	0.00162	CcSEcCtD
Loxapine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000737	0.00162	CcSEcCtD
Loxapine—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000736	0.00161	CcSEcCtD
Loxapine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000736	0.00161	CcSEcCtD
Loxapine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000734	0.00161	CcSEcCtD
Loxapine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000731	0.0016	CcSEcCtD
Loxapine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000731	0.0016	CcSEcCtD
Loxapine—Alopecia—Etoposide—peripheral nervous system neoplasm	0.00073	0.0016	CcSEcCtD
Loxapine—Oedema—Vincristine—peripheral nervous system neoplasm	0.000725	0.00159	CcSEcCtD
Loxapine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000722	0.00158	CcSEcCtD
Loxapine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000718	0.00157	CcSEcCtD
Loxapine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000712	0.00156	CcSEcCtD
Loxapine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000712	0.00156	CcSEcCtD
Loxapine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000711	0.00156	CcSEcCtD
Loxapine—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000709	0.00156	CcSEcCtD
Loxapine—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000708	0.00155	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000705	0.00155	CcSEcCtD
Loxapine—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000704	0.00154	CcSEcCtD
Loxapine—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.000703	0.00154	CcSEcCtD
Loxapine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000703	0.00154	CcSEcCtD
Loxapine—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000703	0.00154	CcSEcCtD
Loxapine—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000702	0.00154	CcSEcCtD
Loxapine—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000702	0.00154	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000699	0.00153	CcSEcCtD
Loxapine—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000693	0.00152	CcSEcCtD
Loxapine—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.000691	0.00152	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000683	0.0015	CcSEcCtD
Loxapine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.00068	0.00149	CcSEcCtD
Loxapine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00068	0.00149	CcSEcCtD
Loxapine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000677	0.00148	CcSEcCtD
Loxapine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.000675	0.00148	CcSEcCtD
Loxapine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00067	0.00147	CcSEcCtD
Loxapine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000669	0.00147	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000668	0.00146	CcSEcCtD
Loxapine—HTR1A—cerebellum—peripheral nervous system neoplasm	0.000667	0.00221	CbGeAlD
Loxapine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000661	0.00145	CcSEcCtD
Loxapine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000656	0.00144	CcSEcCtD
Loxapine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000656	0.00144	CcSEcCtD
Loxapine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000655	0.00144	CcSEcCtD
Loxapine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000651	0.00143	CcSEcCtD
Loxapine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000649	0.00142	CcSEcCtD
Loxapine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000648	0.00142	CcSEcCtD
Loxapine—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000644	0.00141	CcSEcCtD
Loxapine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000643	0.00141	CcSEcCtD
Loxapine—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000641	0.0014	CcSEcCtD
Loxapine—HTR7—cerebellum—peripheral nervous system neoplasm	0.000638	0.00211	CbGeAlD
Loxapine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000636	0.00139	CcSEcCtD
Loxapine—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000632	0.00139	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000632	0.00139	CcSEcCtD
Loxapine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000631	0.00138	CcSEcCtD
Loxapine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000631	0.00138	CcSEcCtD
Loxapine—Rash—Topotecan—peripheral nervous system neoplasm	0.000631	0.00138	CcSEcCtD
Loxapine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00063	0.00138	CcSEcCtD
Loxapine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000628	0.00138	CcSEcCtD
Loxapine—Cough—Etoposide—peripheral nervous system neoplasm	0.000628	0.00138	CcSEcCtD
Loxapine—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000627	0.00138	CcSEcCtD
Loxapine—Headache—Topotecan—peripheral nervous system neoplasm	0.000627	0.00137	CcSEcCtD
Loxapine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000626	0.00137	CcSEcCtD
Loxapine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000626	0.00137	CcSEcCtD
Loxapine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000626	0.00137	CcSEcCtD
Loxapine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000625	0.00137	CcSEcCtD
Loxapine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000625	0.00137	CcSEcCtD
Loxapine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000625	0.00137	CcSEcCtD
Loxapine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000625	0.00137	CcSEcCtD
Loxapine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000623	0.00137	CcSEcCtD
Loxapine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000623	0.00136	CcSEcCtD
Loxapine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000622	0.00136	CcSEcCtD
Loxapine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000622	0.00136	CcSEcCtD
Loxapine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000621	0.00136	CcSEcCtD
Loxapine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00062	0.00136	CcSEcCtD
Loxapine—Constipation—Vincristine—peripheral nervous system neoplasm	0.00062	0.00136	CcSEcCtD
Loxapine—Rash—Melphalan—peripheral nervous system neoplasm	0.000618	0.00135	CcSEcCtD
Loxapine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000617	0.00135	CcSEcCtD
Loxapine—ADRA1A—cerebellum—peripheral nervous system neoplasm	0.000615	0.00204	CbGeAlD
Loxapine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000612	0.00134	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000611	0.00134	CcSEcCtD
Loxapine—DRD2—cerebellum—peripheral nervous system neoplasm	0.000603	0.002	CbGeAlD
Loxapine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000599	0.00131	CcSEcCtD
Loxapine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000598	0.00131	CcSEcCtD
Loxapine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000594	0.0013	CcSEcCtD
Loxapine—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000592	0.0013	CcSEcCtD
Loxapine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000589	0.00129	CcSEcCtD
Loxapine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000589	0.00129	CcSEcCtD
Loxapine—ADRA2C—cerebellum—peripheral nervous system neoplasm	0.000586	0.00194	CbGeAlD
Loxapine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000582	0.00128	CcSEcCtD
Loxapine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000582	0.00128	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000579	0.00127	CcSEcCtD
Loxapine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000575	0.00126	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000575	0.00126	CcSEcCtD
Loxapine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000573	0.00126	CcSEcCtD
Loxapine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000571	0.00125	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000566	0.00124	CcSEcCtD
Loxapine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000554	0.00121	CcSEcCtD
Loxapine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000553	0.00121	CcSEcCtD
Loxapine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000548	0.0012	CcSEcCtD
Loxapine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00054	0.00118	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000535	0.00117	CcSEcCtD
Loxapine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000534	0.00117	CcSEcCtD
Loxapine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000532	0.00117	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000528	0.00116	CcSEcCtD
Loxapine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000528	0.00116	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000527	0.00116	CcSEcCtD
Loxapine—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000527	0.00115	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000523	0.00115	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000523	0.00115	CcSEcCtD
Loxapine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000522	0.00114	CcSEcCtD
Loxapine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00052	0.00114	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000516	0.00113	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000516	0.00113	CcSEcCtD
Loxapine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000511	0.00112	CcSEcCtD
Loxapine—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000507	0.00111	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000507	0.00111	CcSEcCtD
Loxapine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000506	0.00111	CcSEcCtD
Loxapine—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000503	0.0011	CcSEcCtD
Loxapine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000502	0.0011	CcSEcCtD
Loxapine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000497	0.00109	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000489	0.00107	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000487	0.00107	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000484	0.00106	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000484	0.00106	CcSEcCtD
Loxapine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000482	0.00106	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000481	0.00106	CcSEcCtD
Loxapine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000479	0.00105	CcSEcCtD
Loxapine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000478	0.00105	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000477	0.00105	CcSEcCtD
Loxapine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000474	0.00104	CcSEcCtD
Loxapine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000474	0.00104	CcSEcCtD
Loxapine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000472	0.00103	CcSEcCtD
Loxapine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000471	0.00103	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000469	0.00103	CcSEcCtD
Loxapine—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.000468	0.00155	CbGeAlD
Loxapine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000465	0.00102	CcSEcCtD
Loxapine—Azelastine—ABCB1—peripheral nervous system neoplasm	0.000464	0.184	CrCbGaD
Loxapine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000463	0.00102	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000461	0.00101	CcSEcCtD
Loxapine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000461	0.00101	CcSEcCtD
Loxapine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.00046	0.00101	CcSEcCtD
Loxapine—Rash—Vincristine—peripheral nervous system neoplasm	0.000457	0.001	CcSEcCtD
Loxapine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000456	0.001	CcSEcCtD
Loxapine—Headache—Vincristine—peripheral nervous system neoplasm	0.000454	0.000995	CcSEcCtD
Loxapine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000447	0.000979	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000445	0.000976	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000432	0.000948	CcSEcCtD
Loxapine—Nausea—Vincristine—peripheral nervous system neoplasm	0.00043	0.000943	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000429	0.000939	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000426	0.000935	CcSEcCtD
Loxapine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000421	0.000923	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.00042	0.000921	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000915	CcSEcCtD
Loxapine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000415	0.00091	CcSEcCtD
Loxapine—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000409	0.000897	CcSEcCtD
Loxapine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000407	0.000893	CcSEcCtD
Loxapine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000404	0.000886	CcSEcCtD
Loxapine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000404	0.000885	CcSEcCtD
Loxapine—Olanzapine—ABCB1—peripheral nervous system neoplasm	0.000399	0.158	CrCbGaD
Loxapine—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000398	0.00132	CbGeAlD
Loxapine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000396	0.000867	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000865	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000389	0.000852	CcSEcCtD
Loxapine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000388	0.000851	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000388	0.00085	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.000847	CcSEcCtD
Loxapine—Trazodone—ABCB1—peripheral nervous system neoplasm	0.000385	0.153	CrCbGaD
Loxapine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000381	0.000834	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.00038	0.000833	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.00083	CcSEcCtD
Loxapine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000373	0.000818	CcSEcCtD
Loxapine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.00037	0.000812	CcSEcCtD
Loxapine—Rash—Etoposide—peripheral nervous system neoplasm	0.00037	0.000811	CcSEcCtD
Loxapine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00037	0.000811	CcSEcCtD
Loxapine—Headache—Etoposide—peripheral nervous system neoplasm	0.000368	0.000806	CcSEcCtD
Loxapine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.000802	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000365	0.000801	CcSEcCtD
Loxapine—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000362	0.000793	CcSEcCtD
Loxapine—Clobazam—ABCB1—peripheral nervous system neoplasm	0.000361	0.143	CrCbGaD
Loxapine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000361	0.000791	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.000786	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000354	0.000777	CcSEcCtD
Loxapine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000352	0.000771	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.000771	CcSEcCtD
Loxapine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000349	0.000766	CcSEcCtD
Loxapine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000349	0.000764	CcSEcCtD
Loxapine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000348	0.000763	CcSEcCtD
Loxapine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000343	0.000752	CcSEcCtD
Loxapine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000343	0.000751	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000336	0.000736	CcSEcCtD
Loxapine—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000335	0.000733	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000732	CcSEcCtD
Loxapine—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000727	CcSEcCtD
Loxapine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000329	0.000721	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000719	CcSEcCtD
Loxapine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000326	0.000714	CcSEcCtD
Loxapine—Shock—Epirubicin—peripheral nervous system neoplasm	0.000324	0.00071	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.000708	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000707	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000706	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000322	0.000706	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000704	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000696	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000681	CcSEcCtD
Loxapine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000674	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000673	CcSEcCtD
Loxapine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000304	0.000667	CcSEcCtD
Loxapine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000657	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000654	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000653	CcSEcCtD
Loxapine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000652	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000651	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000648	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000643	CcSEcCtD
Loxapine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000641	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000624	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000623	CcSEcCtD
Loxapine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000622	CcSEcCtD
Loxapine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000617	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000604	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000599	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000595	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000594	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000593	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000576	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.000575	CcSEcCtD
Loxapine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000571	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.00055	CcSEcCtD
Loxapine—Trifluoperazine—ABCB1—peripheral nervous system neoplasm	0.000249	0.099	CrCbGaD
Loxapine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000531	CcSEcCtD
Loxapine—Quetiapine—ABCB1—peripheral nervous system neoplasm	0.000242	0.096	CrCbGaD
Loxapine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000236	0.000517	CcSEcCtD
Loxapine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000233	0.00051	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000492	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.000479	CcSEcCtD
Loxapine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000477	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.000472	CcSEcCtD
Loxapine—Diazepam—ABCB1—peripheral nervous system neoplasm	0.000211	0.0836	CrCbGaD
Loxapine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000459	CcSEcCtD
Loxapine—Clozapine—ABCB1—peripheral nervous system neoplasm	0.000208	0.0826	CrCbGaD
Loxapine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000455	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000454	CcSEcCtD
Loxapine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000452	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000441	CcSEcCtD
Loxapine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000428	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000424	CcSEcCtD
Loxapine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000421	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.00042	CcSEcCtD
Loxapine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000418	CcSEcCtD
Loxapine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000396	CcSEcCtD
Loxapine—ADRA1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.23e-05	9.32e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.23e-05	9.32e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.23e-05	9.31e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.23e-05	9.3e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.22e-05	9.27e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.21e-05	9.25e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.21e-05	9.25e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.19e-05	9.16e-05	CbGpPWpGaD
Loxapine—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.19e-05	9.14e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.18e-05	9.12e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.17e-05	9.05e-05	CbGpPWpGaD
Loxapine—DRD4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.15e-05	8.99e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.13e-05	8.91e-05	CbGpPWpGaD
Loxapine—CHRM4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.12e-05	8.87e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.12e-05	8.84e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.1e-05	8.79e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.09e-05	8.75e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.09e-05	8.74e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.09e-05	8.72e-05	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	2.07e-05	8.66e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.06e-05	8.59e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.05e-05	8.54e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.04e-05	8.53e-05	CbGpPWpGaD
Loxapine—CHRM5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.03e-05	8.5e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.03e-05	8.48e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.03e-05	8.48e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.02e-05	8.45e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.02e-05	8.44e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.02e-05	8.44e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.02e-05	8.42e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.01e-05	8.41e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.01e-05	8.38e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2e-05	8.36e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.99e-05	8.33e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.99e-05	8.31e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.99e-05	8.3e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.99e-05	8.3e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.98e-05	8.29e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.98e-05	8.28e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.98e-05	8.26e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.97e-05	8.24e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.97e-05	8.21e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.96e-05	8.17e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.95e-05	8.16e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.95e-05	8.13e-05	CbGpPWpGaD
Loxapine—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.94e-05	8.1e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.93e-05	8.06e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.92e-05	8.02e-05	CbGpPWpGaD
Loxapine—DRD3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.91e-05	7.99e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.9e-05	7.94e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.9e-05	7.91e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.89e-05	7.87e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.87e-05	7.81e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.87e-05	7.8e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.87e-05	7.79e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.86e-05	7.75e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.85e-05	7.74e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.85e-05	7.71e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.84e-05	7.69e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.82e-05	7.6e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.82e-05	7.59e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.81e-05	7.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.81e-05	7.56e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.79e-05	7.49e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.79e-05	7.47e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.78e-05	7.45e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.78e-05	7.42e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.77e-05	7.4e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.77e-05	7.39e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.76e-05	7.37e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.76e-05	7.35e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.76e-05	7.35e-05	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.74e-05	7.28e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.74e-05	7.27e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.74e-05	7.27e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.74e-05	7.25e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.73e-05	7.24e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.73e-05	7.22e-05	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.73e-05	7.21e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.73e-05	7.21e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.71e-05	7.16e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.71e-05	7.14e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.71e-05	7.12e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.69e-05	7.07e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.69e-05	7.06e-05	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.67e-05	6.96e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.67e-05	6.96e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.66e-05	6.93e-05	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.66e-05	6.93e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.65e-05	6.9e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.64e-05	6.86e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.64e-05	6.86e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.63e-05	6.82e-05	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.61e-05	6.74e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.61e-05	6.72e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.6e-05	6.67e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.6e-05	6.67e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.59e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.59e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.58e-05	6.61e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.58e-05	6.58e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.57e-05	6.57e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.57e-05	6.57e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.57e-05	6.56e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.57e-05	6.55e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.57e-05	6.55e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.57e-05	6.54e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.56e-05	6.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.56e-05	6.51e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.54e-05	6.45e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.54e-05	6.43e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.51e-05	6.32e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.51e-05	6.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.51e-05	6.29e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.5e-05	6.26e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.48e-05	6.19e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.48e-05	6.18e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.48e-05	6.17e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.47e-05	6.15e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.47e-05	6.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.46e-05	6.12e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.46e-05	6.11e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.45e-05	6.07e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.45e-05	6.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.45e-05	6.06e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.45e-05	6.04e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.44e-05	6.02e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.44e-05	6.01e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.44e-05	6e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.43e-05	5.99e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.43e-05	5.98e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.43e-05	5.97e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.43e-05	5.97e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.43e-05	5.97e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.43e-05	5.96e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.43e-05	5.96e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.42e-05	5.95e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.42e-05	5.93e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.42e-05	5.93e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.41e-05	5.91e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.41e-05	5.9e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.41e-05	5.89e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.4e-05	5.85e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.4e-05	5.83e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.39e-05	5.81e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.38e-05	5.78e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.38e-05	5.75e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.37e-05	5.71e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.37e-05	5.71e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.37e-05	5.71e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.36e-05	5.67e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.35e-05	5.64e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.35e-05	5.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.35e-05	5.63e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.34e-05	5.59e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.34e-05	5.58e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.33e-05	5.55e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.33e-05	5.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.32e-05	5.51e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.31e-05	5.47e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.31e-05	5.46e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.31e-05	5.46e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.31e-05	5.45e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.3e-05	5.43e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.3e-05	5.42e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.3e-05	5.41e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.29e-05	5.4e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.29e-05	5.39e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.29e-05	5.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.28e-05	5.36e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.28e-05	5.36e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.28e-05	5.35e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-05	5.21e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.24e-05	5.16e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.23e-05	5.14e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.23e-05	5.13e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.22e-05	5.08e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.22e-05	5.07e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.21e-05	5.04e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.21e-05	5.04e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.2e-05	5.01e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.2e-05	4.99e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.19e-05	4.98e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.19e-05	4.97e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.19e-05	4.97e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.19e-05	4.95e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.18e-05	4.92e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-05	4.9e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.17e-05	4.9e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-05	4.89e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.16e-05	4.85e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.16e-05	4.82e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.14e-05	4.76e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.13e-05	4.73e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.11e-05	4.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.11e-05	4.64e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.11e-05	4.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.11e-05	4.62e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.1e-05	4.61e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.1e-05	4.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-05	4.57e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.09e-05	4.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-05	4.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.09e-05	4.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.06e-05	4.42e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.06e-05	4.42e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.05e-05	4.4e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.05e-05	4.38e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.04e-05	4.34e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	1.03e-05	4.32e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.03e-05	4.28e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.02e-05	4.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.01e-05	4.23e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.01e-05	4.23e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.01e-05	4.21e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.01e-05	4.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.8e-06	4.09e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.65e-06	4.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.35e-06	3.9e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.3e-06	3.88e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.26e-06	3.87e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—peripheral nervous system neoplasm	9.16e-06	3.83e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.15e-06	3.82e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.13e-06	3.81e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.1e-06	3.8e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.07e-06	3.79e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.98e-06	3.75e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.96e-06	3.74e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.94e-06	3.73e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.9e-06	3.72e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.89e-06	3.71e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.75e-06	3.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.73e-06	3.65e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.7e-06	3.63e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.68e-06	3.62e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.65e-06	3.61e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.59e-06	3.59e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.57e-06	3.58e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.52e-06	3.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	8.41e-06	3.51e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.32e-06	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.96e-06	3.32e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.85e-06	3.28e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.73e-06	3.23e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.71e-06	3.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.68e-06	3.21e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.66e-06	3.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.59e-06	3.17e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.56e-06	3.16e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.03e-06	2.94e-05	CbGpPWpGaD
